Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-12

AUTHORS

Álvaro Hidalgo-Vega, Juan Manuel Ramos-Goñi, Renata Villoro

ABSTRACT

BACKGROUND: Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization. OBJECTIVE: To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain. METHODS: A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated. RESULTS: The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers' willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency. CONCLUSIONS: Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain. More... »

PAGES

917-925

References to SciGraph publications

  • 2013-01. Ranolazine in DRUGS
  • 2009-11. Una valutazione economica di ranolazina add-on nel trattamento dell’angina stabile cronica in PHARMACOECONOMICS ITALIAN RESEARCH ARTICLES
  • 2005-12. Estimating utility data from clinical indicators for patients with stable angina in THE EUROPEAN JOURNAL OF HEALTH ECONOMICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s10198-013-0534-8

    DOI

    http://dx.doi.org/10.1007/s10198-013-0534-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1032673217

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24122303


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Applied Economics", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Economics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Acetanilides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angina Pectoris", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chronic Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Markov Chains", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Piperazines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Placebos", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ranolazine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Spain", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Facultad de Ciencias Jur\u00eddicas y Sociales de Toledo, An\u00e1lisis Econ\u00f3mico y Finanzas, Castilla-La Mancha University, Cobertizo de San Pedro M\u00e1rtir s/n, 45071, Toledo, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hidalgo-Vega", 
            "givenName": "\u00c1lvaro", 
            "id": "sg:person.01073325344.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073325344.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "HTA Unit of Canary Islands Health Service, C/Calvario no 271-B 1\u00b0 IZQ, 38350, Tacoronte, Canary Islands, Spain", 
                "Red de Investigaci\u00f3n de Servicios Sanitarios En Cronicidad (REDISSEC), Tacoronte, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ramos-Go\u00f1i", 
            "givenName": "Juan Manuel", 
            "id": "sg:person.01256127554.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256127554.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Weber, Econom\u00eda y Salud, C/Norias 123. Majadahonda, 28221, Madrid, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Villoro", 
            "givenName": "Renata", 
            "id": "sg:person.01172643353.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172643353.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1016/j.jacc.2006.05.044", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006994570"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/eurheartj/ehi109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007626206"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.jacc.2003.11.045", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007720639"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40265-012-0005-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009325068", 
              "https://doi.org/10.1007/s40265-012-0005-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0213-9111(02)71933-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011659047"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/archinternmed.2009.295", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014064741"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1157/13092800", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015903997"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1157/13092800", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015903997"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10198-005-0309-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021229261", 
              "https://doi.org/10.1007/s10198-005-0309-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10198-005-0309-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021229261", 
              "https://doi.org/10.1007/s10198-005-0309-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa070829", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022199950"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/(sici)1099-1050(199905)8:3<269::aid-hec425>3.0.co;2-d", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024825968"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s1131-3587(07)75771-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024930570"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/hrt.81.4.352", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025707552"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/jama.291.3.309", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027184649"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/archinte.168.12.1310", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029747652"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/bmj.39129.442164.55", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030129185"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.pharmthera.2011.11.003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031808211"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.jacc.2013.02.011", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034769148"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/circoutcomes.108.829523", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035595502"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/circoutcomes.108.829523", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035595502"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00005650-200503000-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038494268"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00005650-200503000-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038494268"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/circoutcomes.108.798009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041882379"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1161/circoutcomes.108.798009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041882379"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/heart.87.2.140", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043165484"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/europace/eus400", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043954749"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03320519", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045655885", 
              "https://doi.org/10.1007/bf03320519"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1001/jama.297.16.1775", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047077933"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0735-1097(94)00397-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050546444"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.18553/jmcp.2005.11.4.300", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1068660548"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077336083", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-12", 
        "datePublishedReg": "2014-12-01", 
        "description": "BACKGROUND: Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization.\nOBJECTIVE: To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain.\nMETHODS: A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated.\nRESULTS: The incremental cost-utility ratio was \u20ac8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers' willingness to pay is \u20ac15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency.\nCONCLUSIONS: Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s10198-013-0534-8", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1297512", 
            "issn": [
              "1439-3972", 
              "1439-6637"
            ], 
            "name": "The European Journal of Health Economics", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "9", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "name": "Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain", 
        "pagination": "917-925", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "9ba701864c0fb31f83d75985e065bd66c13021c0cff6186977db54b30635cb4e"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24122303"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101134867"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s10198-013-0534-8"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1032673217"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s10198-013-0534-8", 
          "https://app.dimensions.ai/details/publication/pub.1032673217"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T19:09", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000513.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs10198-013-0534-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-013-0534-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-013-0534-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-013-0534-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-013-0534-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    226 TRIPLES      21 PREDICATES      70 URIs      35 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s10198-013-0534-8 schema:about N0c2580fc70874be1a73a6a8cc8260497
    2 N0fe4b9eb133a4262ba771ac5270855d3
    3 N22e10743913d4131ae8db9915b2adf05
    4 N26adce498de341a283512eebf57b66ff
    5 N4159ee3918e245b58cf40c78b492d3c9
    6 N500735300083481b86fb1239b76eaef4
    7 N516a87e24730470f8dfc17786f1b025b
    8 N6ef3398038ba446f96ee3d5e7e557455
    9 N7b0dbd109a9445eb9d281ed57a7e43af
    10 N848f34527faf4da09f00017d3c0de066
    11 N90e77fc0f7c14531941d6ff07ff0c4d3
    12 Nbdaee48fe63846d5a87d709e416ad8a4
    13 Nd4deedf6813c437492a5fa2746a80c97
    14 Nfb25a9db44cc4c08b5b58b3fe5e2056c
    15 anzsrc-for:14
    16 anzsrc-for:1402
    17 schema:author Nce5ffa21ef8649809be681d9005fc86f
    18 schema:citation sg:pub.10.1007/bf03320519
    19 sg:pub.10.1007/s10198-005-0309-y
    20 sg:pub.10.1007/s40265-012-0005-z
    21 https://app.dimensions.ai/details/publication/pub.1077336083
    22 https://doi.org/10.1001/archinte.168.12.1310
    23 https://doi.org/10.1001/archinternmed.2009.295
    24 https://doi.org/10.1001/jama.291.3.309
    25 https://doi.org/10.1001/jama.297.16.1775
    26 https://doi.org/10.1002/(sici)1099-1050(199905)8:3<269::aid-hec425>3.0.co;2-d
    27 https://doi.org/10.1016/0735-1097(94)00397-9
    28 https://doi.org/10.1016/j.jacc.2003.11.045
    29 https://doi.org/10.1016/j.jacc.2006.05.044
    30 https://doi.org/10.1016/j.jacc.2013.02.011
    31 https://doi.org/10.1016/j.pharmthera.2011.11.003
    32 https://doi.org/10.1016/s0213-9111(02)71933-x
    33 https://doi.org/10.1016/s1131-3587(07)75771-0
    34 https://doi.org/10.1056/nejmoa070829
    35 https://doi.org/10.1093/eurheartj/ehi109
    36 https://doi.org/10.1093/europace/eus400
    37 https://doi.org/10.1097/00005650-200503000-00003
    38 https://doi.org/10.1136/bmj.39129.442164.55
    39 https://doi.org/10.1136/heart.87.2.140
    40 https://doi.org/10.1136/hrt.81.4.352
    41 https://doi.org/10.1157/13092800
    42 https://doi.org/10.1161/circoutcomes.108.798009
    43 https://doi.org/10.1161/circoutcomes.108.829523
    44 https://doi.org/10.18553/jmcp.2005.11.4.300
    45 schema:datePublished 2014-12
    46 schema:datePublishedReg 2014-12-01
    47 schema:description BACKGROUND: Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization. OBJECTIVE: To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain. METHODS: A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated. RESULTS: The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers' willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency. CONCLUSIONS: Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.
    48 schema:genre research_article
    49 schema:inLanguage en
    50 schema:isAccessibleForFree false
    51 schema:isPartOf N1701f2a5b4c94dbc8e967a112e296b14
    52 N9ec5481766d04b5caa0ae64f34c27fcb
    53 sg:journal.1297512
    54 schema:name Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain
    55 schema:pagination 917-925
    56 schema:productId N28e3c4719c3442c68aa8902956b1bcf5
    57 Na767bf55fb4b48fea0a72131ae6f8fca
    58 Ncef3f955b5b74f439349216633c900fb
    59 Nd6ad9086bb1f431dba558e19c798d98a
    60 Ndd1f9a6dd476457b939c29ceaebc50d0
    61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032673217
    62 https://doi.org/10.1007/s10198-013-0534-8
    63 schema:sdDatePublished 2019-04-10T19:09
    64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    65 schema:sdPublisher N9fa546ba84634053839a258676344f52
    66 schema:url http://link.springer.com/10.1007%2Fs10198-013-0534-8
    67 sgo:license sg:explorer/license/
    68 sgo:sdDataset articles
    69 rdf:type schema:ScholarlyArticle
    70 N0c2580fc70874be1a73a6a8cc8260497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    71 schema:name Placebos
    72 rdf:type schema:DefinedTerm
    73 N0fdb318b7a274d92b14f98de8e026dd3 schema:name Facultad de Ciencias Jurídicas y Sociales de Toledo, Análisis Económico y Finanzas, Castilla-La Mancha University, Cobertizo de San Pedro Mártir s/n, 45071, Toledo, Spain
    74 rdf:type schema:Organization
    75 N0fe4b9eb133a4262ba771ac5270855d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    76 schema:name Angina Pectoris
    77 rdf:type schema:DefinedTerm
    78 N1701f2a5b4c94dbc8e967a112e296b14 schema:issueNumber 9
    79 rdf:type schema:PublicationIssue
    80 N22e10743913d4131ae8db9915b2adf05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    81 schema:name Markov Chains
    82 rdf:type schema:DefinedTerm
    83 N26adce498de341a283512eebf57b66ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    84 schema:name Cost-Benefit Analysis
    85 rdf:type schema:DefinedTerm
    86 N28e3c4719c3442c68aa8902956b1bcf5 schema:name readcube_id
    87 schema:value 9ba701864c0fb31f83d75985e065bd66c13021c0cff6186977db54b30635cb4e
    88 rdf:type schema:PropertyValue
    89 N3889aa2fa9f248b69f12f59f13f1de2d schema:name Weber, Economía y Salud, C/Norias 123. Majadahonda, 28221, Madrid, Spain
    90 rdf:type schema:Organization
    91 N4159ee3918e245b58cf40c78b492d3c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Enzyme Inhibitors
    93 rdf:type schema:DefinedTerm
    94 N500735300083481b86fb1239b76eaef4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Acetanilides
    96 rdf:type schema:DefinedTerm
    97 N516a87e24730470f8dfc17786f1b025b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Piperazines
    99 rdf:type schema:DefinedTerm
    100 N53f909d9fa87419ca5575507c0a3df68 schema:name HTA Unit of Canary Islands Health Service, C/Calvario no 271-B 1° IZQ, 38350, Tacoronte, Canary Islands, Spain
    101 Red de Investigación de Servicios Sanitarios En Cronicidad (REDISSEC), Tacoronte, Spain
    102 rdf:type schema:Organization
    103 N56de100254644d98ab56f76010ecee81 rdf:first sg:person.01172643353.34
    104 rdf:rest rdf:nil
    105 N6ef3398038ba446f96ee3d5e7e557455 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Spain
    107 rdf:type schema:DefinedTerm
    108 N7b0dbd109a9445eb9d281ed57a7e43af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Chronic Disease
    110 rdf:type schema:DefinedTerm
    111 N848f34527faf4da09f00017d3c0de066 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Female
    113 rdf:type schema:DefinedTerm
    114 N8fb984aa37644922bd7d736c7d447242 rdf:first sg:person.01256127554.13
    115 rdf:rest N56de100254644d98ab56f76010ecee81
    116 N90e77fc0f7c14531941d6ff07ff0c4d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Humans
    118 rdf:type schema:DefinedTerm
    119 N9ec5481766d04b5caa0ae64f34c27fcb schema:volumeNumber 15
    120 rdf:type schema:PublicationVolume
    121 N9fa546ba84634053839a258676344f52 schema:name Springer Nature - SN SciGraph project
    122 rdf:type schema:Organization
    123 Na767bf55fb4b48fea0a72131ae6f8fca schema:name nlm_unique_id
    124 schema:value 101134867
    125 rdf:type schema:PropertyValue
    126 Nbdaee48fe63846d5a87d709e416ad8a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Ranolazine
    128 rdf:type schema:DefinedTerm
    129 Nce5ffa21ef8649809be681d9005fc86f rdf:first sg:person.01073325344.65
    130 rdf:rest N8fb984aa37644922bd7d736c7d447242
    131 Ncef3f955b5b74f439349216633c900fb schema:name pubmed_id
    132 schema:value 24122303
    133 rdf:type schema:PropertyValue
    134 Nd4deedf6813c437492a5fa2746a80c97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Male
    136 rdf:type schema:DefinedTerm
    137 Nd6ad9086bb1f431dba558e19c798d98a schema:name dimensions_id
    138 schema:value pub.1032673217
    139 rdf:type schema:PropertyValue
    140 Ndd1f9a6dd476457b939c29ceaebc50d0 schema:name doi
    141 schema:value 10.1007/s10198-013-0534-8
    142 rdf:type schema:PropertyValue
    143 Nfb25a9db44cc4c08b5b58b3fe5e2056c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Middle Aged
    145 rdf:type schema:DefinedTerm
    146 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
    147 schema:name Economics
    148 rdf:type schema:DefinedTerm
    149 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
    150 schema:name Applied Economics
    151 rdf:type schema:DefinedTerm
    152 sg:journal.1297512 schema:issn 1439-3972
    153 1439-6637
    154 schema:name The European Journal of Health Economics
    155 rdf:type schema:Periodical
    156 sg:person.01073325344.65 schema:affiliation N0fdb318b7a274d92b14f98de8e026dd3
    157 schema:familyName Hidalgo-Vega
    158 schema:givenName Álvaro
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073325344.65
    160 rdf:type schema:Person
    161 sg:person.01172643353.34 schema:affiliation N3889aa2fa9f248b69f12f59f13f1de2d
    162 schema:familyName Villoro
    163 schema:givenName Renata
    164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172643353.34
    165 rdf:type schema:Person
    166 sg:person.01256127554.13 schema:affiliation N53f909d9fa87419ca5575507c0a3df68
    167 schema:familyName Ramos-Goñi
    168 schema:givenName Juan Manuel
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256127554.13
    170 rdf:type schema:Person
    171 sg:pub.10.1007/bf03320519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045655885
    172 https://doi.org/10.1007/bf03320519
    173 rdf:type schema:CreativeWork
    174 sg:pub.10.1007/s10198-005-0309-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1021229261
    175 https://doi.org/10.1007/s10198-005-0309-y
    176 rdf:type schema:CreativeWork
    177 sg:pub.10.1007/s40265-012-0005-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1009325068
    178 https://doi.org/10.1007/s40265-012-0005-z
    179 rdf:type schema:CreativeWork
    180 https://app.dimensions.ai/details/publication/pub.1077336083 schema:CreativeWork
    181 https://doi.org/10.1001/archinte.168.12.1310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029747652
    182 rdf:type schema:CreativeWork
    183 https://doi.org/10.1001/archinternmed.2009.295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014064741
    184 rdf:type schema:CreativeWork
    185 https://doi.org/10.1001/jama.291.3.309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027184649
    186 rdf:type schema:CreativeWork
    187 https://doi.org/10.1001/jama.297.16.1775 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047077933
    188 rdf:type schema:CreativeWork
    189 https://doi.org/10.1002/(sici)1099-1050(199905)8:3<269::aid-hec425>3.0.co;2-d schema:sameAs https://app.dimensions.ai/details/publication/pub.1024825968
    190 rdf:type schema:CreativeWork
    191 https://doi.org/10.1016/0735-1097(94)00397-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050546444
    192 rdf:type schema:CreativeWork
    193 https://doi.org/10.1016/j.jacc.2003.11.045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007720639
    194 rdf:type schema:CreativeWork
    195 https://doi.org/10.1016/j.jacc.2006.05.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006994570
    196 rdf:type schema:CreativeWork
    197 https://doi.org/10.1016/j.jacc.2013.02.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034769148
    198 rdf:type schema:CreativeWork
    199 https://doi.org/10.1016/j.pharmthera.2011.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031808211
    200 rdf:type schema:CreativeWork
    201 https://doi.org/10.1016/s0213-9111(02)71933-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011659047
    202 rdf:type schema:CreativeWork
    203 https://doi.org/10.1016/s1131-3587(07)75771-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024930570
    204 rdf:type schema:CreativeWork
    205 https://doi.org/10.1056/nejmoa070829 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022199950
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1093/eurheartj/ehi109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007626206
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1093/europace/eus400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043954749
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1097/00005650-200503000-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038494268
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1136/bmj.39129.442164.55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030129185
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1136/heart.87.2.140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043165484
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1136/hrt.81.4.352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025707552
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1157/13092800 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015903997
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1161/circoutcomes.108.798009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041882379
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1161/circoutcomes.108.829523 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035595502
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.18553/jmcp.2005.11.4.300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068660548
    226 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...